MCID: RTN024
MIFTS: 75

Retinoblastoma malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Cancer diseases, Immune diseases, Neuronal diseases, Endocrine diseases

Aliases & Classifications for Retinoblastoma

About this section
Sources:
11Disease Ontology, 12diseasecard, 13DISEASES, 23GeneReviews, 24GeneTests, 25Genetics Home Reference, 26GTR, 30ICD10 via Orphanet, 36MedGen, 38MeSH, 39MESH via Orphanet, 44NCIt, 47NIH Rare Diseases, 49Novoseek, 51OMIM, 53Orphanet, 61SNOMED-CT, 63The Human Phenotype Ontology, 67UMLS, 68UMLS via Orphanet, 69UniProtKB/Swiss-Prot, 70Wikipedia
See all MalaCards sources

Aliases & Descriptions for Retinoblastoma:

Name: Retinoblastoma 51 11 70 23 47 24 25 53 26 12 49 13 67
Trilateral Retinoblastoma 11 26 13 67
Rb 11 47 25 69
Glioma, Retinal 70 25
Childhood Cancer Retinoblastoma 69
Malignant Neoplasm of Retina 67
Retinoblastoma, Trilateral 51
 
Eye Cancer, Retinoblastoma 47
Neuroblastoma of Retina 11
Rb - Retinoblastoma 11
Retinal Neoplasms 67
Retinal Cancer 47
Retinal Tumor 47

Characteristics:

Orphanet epidemiological data:

53
retinoblastoma:
Inheritance: Autosomal dominant,Not applicable; Prevalence: <1/1000000 (Europe),1-9/100000 (Europe),1-9/100000 (Worldwide); Age of onset: Antenatal,Childhood,Infancy; Age of death: any age

HPO:

63

GeneReviews:

23
Penetrance: see genotype-phenotype correlations...


Classifications:

Orphanet: 53 
Rare eye diseases


External Ids:

OMIM51 180200
Disease Ontology11 DOID:4647, DOID:768
MeSH38 D012175
NCIt44 C6956, C7541
Orphanet53 ORPHA790
MESH via Orphanet39 D012175
UMLS via Orphanet68 C0035335
ICD10 via Orphanet30 C69.2
MedGen36 C0035335

Summaries for Retinoblastoma

About this section
NIH Rare Diseases:47 Retinoblastoma (RB) is a rare type of eye cancer in the retina that typically develops before the age of 5. It usually affects only one eye, but 1/3 of children with RB develop cancer in both eyes. The first sign is typically a visible whiteness in the pupil called cat's eye reflex or leukocoria, which is particularly noticeable in photographs taken with a flash. Other signs and symptoms include strabismus; persistent eye pain, redness or irritation; and blindness or poor vision in the affected eye(s). Retinoblastoma is caused by mutations in the RB1 gene. In about 60% of people with retinoblastoma, mutations are not inherited and occur only in retinal cells. In the other 40% of individuals, mutations are inherited from a parent in an autosomal dominant pattern and can be found in all body cells. Retinoblastoma that is caused by an inherited mutation is called hereditary retinoblastoma. Hereditary retinoblastoma usually occurs at a younger age than retinoblastoma that is not inherited (15 months vs. 24 months). Retinoblastoma that occurs in only one eye is usually not inherited. Retinoblastoma that occurs in both eyes is thought to be inherited. Last updated: 4/4/2012

MalaCards based summary: Retinoblastoma, also known as trilateral retinoblastoma, is related to extraocular retinoblastoma and intraocular retinoblastoma, and has symptoms including retinoblastoma, cleft palate and leukocoria. An important gene associated with Retinoblastoma is RB1 (RB Transcriptional Corepressor 1), and among its related pathways are Id Signaling Pathway and Sumoylation by RanBP2 regulates transcriptional repression. The drug cyclophosphamide has been mentioned in the context of this disorder. Affiliated tissues include the pineal or suprasellar region, eye and retina, and related mouse phenotypes are digestive/alimentary and muscle.

Disease Ontology:11 A retinal cell cancer and malignant neoplasm of retina and neuroblastoma and neuroendocrine tumors that derives from the tissues of the retina.

Genetics Home Reference:25 Retinoblastoma is a rare type of eye cancer that usually develops in early childhood, typically before the age of 5. This form of cancer develops in the retina, which is the specialized light-sensitive tissue at the back of the eye that detects light and color.

OMIM:51 Retinoblastoma (RB) is an embryonic malignant neoplasm of retinal origin. It almost always presents in early childhood... (180200) more...

UniProtKB/Swiss-Prot:69 Childhood cancer retinoblastoma: Congenital malignant tumor that arises from the nuclear layers of the retina. It occurs in about 1:20'000 live births and represents about 2% of childhood malignancies. It is bilateral in about 30% of cases. Although most RB appear sporadically, about 20% are transmitted as an autosomal dominant trait with incomplete penetrance. The diagnosis is usually made before the age of 2 years when strabismus or a gray to yellow reflex from pupil ('cat eye') is investigated.

Wikipedia:70 Retinoblastoma (Rb) is a rare form of cancer that rapidly develops from the immature cells of a retina,... more...

GeneReviews for NBK1452

Related Diseases for Retinoblastoma

About this section

Diseases in the Retinoblastoma family:

Familial Retinoblastoma

Diseases related to Retinoblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 227)
idRelated DiseaseScoreTop Affiliating Genes
1extraocular retinoblastoma34.2RB1, RBL1
2intraocular retinoblastoma33.9RB1, RBL1
3bilateral retinoblastoma32.5CDK4, E2F1, E2F3, E2F4, MDM2, PRDM2
4unilateral retinoblastoma12.2
5familial retinoblastoma12.1
6pediatric intraocular retinoblastoma12.0
7pediatric extraocular retinoblastoma12.0
8non-hereditary retinoblastoma11.8
9roberts syndrome11.5
10ocular cancer11.1
11blastoma11.0
12retinal cancer11.0
13respiratory bronchiolitis-interstitial lung disease syndrome10.8
14chromosome 13q14 deletion syndrome10.7
15norrie disease10.7
16retinal disease10.7
17chromosome 7p duplication10.6CDK4, MDM2
18epidural spinal canal angiolipoma10.6CDK4, MDM2
19osteogenesis imperfecta10.6CDK4, MDM2
20familial long qt syndrome10.6CDK4, MDM2
21skin lipoma10.6CDK4, MDM2, RB1
22localized chondrosarcoma10.6CDK4, MDM2, RB1
23conjunctivitis10.5CDK4, MDM2
24conventional central osteosarcoma10.5CDK4, MDM2
25pediatric osteosarcoma10.5CDK4, MDM2
26gliosarcoma10.4CDK4, E2F1, MDM2, RB1
27lipoic acid synthetase deficiency10.4CDK4, MDM2
28pleuropulmonary blastoma type 210.4CDK4, MDM2
29esophagus lymphoma10.4E2F3, MDM2, RB1
30hiv-110.3
31breast cancer10.2
32spindle cell liposarcoma10.2CDK4, MDM2
33retinitis10.1
34neuronitis10.1
35prostatitis10.1
36lung cancer10.1
37leukemia10.1
38sarcoma10.0
39lymphoma10.0
40cervicitis10.0
41adenocarcinoma10.0
42prostate cancer9.9
43cellulitis9.9
44thyroiditis9.9
45endotheliitis9.9
46hepatocellular carcinoma9.9
47orbital cellulitis9.9
48esophagitis9.9
49leiomyosarcoma9.9
50pineoblastoma9.9

Graphical network of the top 20 diseases related to Retinoblastoma:



Diseases related to retinoblastoma

Symptoms for Retinoblastoma

About this section

Symptoms by clinical synopsis from OMIM:

180200

Clinical features from OMIM:

180200

Human phenotypes related to Retinoblastoma:

 63 53 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 retinoblastoma63 53 hallmark (90%) Very frequent (99-80%) HP:0009919
2 cleft palate63 HP:0000175
3 leukocoria63 HP:0000555
4 leukemia63 HP:0001909
5 lymphoma63 HP:0002665
6 osteosarcoma63 HP:0002669
7 retinal calcification63 HP:0007862
8 vitreous hemorrhage63 HP:0007902
9 ewing's sarcoma63 HP:0012254

Drugs & Therapeutics for Retinoblastoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Ibrance16 43 PALBOCICLIB Pfizer February 2015
FDA Label: Ibrance
Disease/s that Drug Treats:ER-positive, HER2-negative breast cancer
Indications and Usage:16 IBRANCE is a kinase inhibitor indicated in combination with letrozole for thetreatment of postmenopausal women with estrogen receptor (ER)-positive,human epidermal growth factor receptor 2 (HER2)-negative advanced breastcancer as initial endocrine-based therapy for their metastatic disease. Thisindication is approved under accelerated approval based on progression-freesurvival (PFS). Continued approval for this indication may be contingentupon verification and description of clinical benefit in a confirmatory trial. (1)
DrugBank Targets:14 1. Cyclin-dependent kinase 4;2. Cyclin-dependent kinase 6
Mechanism of Action:16 
Target: cyclin-dependent kinase (CDK) 4 and 6
Action: inhibitor
FDA: Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6. Cyclin D1 and CDK4/6 aredownstream of signaling pathways which lead to cellular proliferation. In vitro, palbociclib reducedcellular proliferation of estrogen receptor (ER)-positive breast cancer cell lines by blocking progressionof the cell from G1 into S phase of the cell cycle. Treatment of breast cancer cell lines with thecombination of palbociclib and antiestrogens leads to decreased retinoblastoma protein (Rb)phosphorylation resulting in reduced E2F expression and signaling and increased growth arrestcompared to treatment with each drug alone. In vitro treatment of ER-positive breast cancer cell lineswith the combination of palbociclib and antiestrogens leads to increased cell senescence, which wassustained for up to 6 days following drug removal. In vivo studies using a patient-derived ER-positivebreast cancer xenograft model demonstrated that the combination of palbociclib and letrozole increasedthe inhibition of Rb phosphorylation, downstream signaling and tumor growth compared to each drugalone.
2
Tasigna16 43 NILOTINIB HYDROCHLORIDE MONOHYDRATE Novartis October 2007
FDA Label: Tasigna
Disease/s that Drug Treats:chronic myelogenous leukemia
Indications and Usage:16 Tasigna is a kinase inhibitor indicated for:The treatment of newly diagnosed adult patients with Philadelphiachromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.The treatment of chronic phase (CP) and accelerated phase (AP) Ph+ CML inadult patients resistant to or intolerant to prior therapy that included imatinib.(1.2)--------------
DrugBank Targets:14 1. Tyrosine-protein kinase ABL1;2. Mast/stem cell growth factor receptor Kit
Mechanism of Action:16 
Target: Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF)
Action: inhibitor of signal transduction
FDA: Nilotinib is an inhibitor of the BCR-ABL kinase. Nilotinib binds to and stabilizes the inactive conformation ofthe kinase domain of ABL protein. In vitro, nilotinib inhibited BCR-ABL mediated proliferation of murineleukemic cell lines and human cell lines derived from patients with Ph+ CML. Under the conditions of theassays, nilotinib was able to overcome imatinib resistance resulting from BCR-ABL kinase mutations, in 32 outof 33 mutations tested. In vivo, nilotinib reduced the tumor size in a murine BCR-ABL xenograft model.Nilotinib inhibited the autophosphorylation of the following kinases at IC50 values as indicated: BCR-ABL (20to 60 nM), PDGFR (69 nM), c-KIT (210 nM), CSF-1R (125 to 250 nM), and DDR1 (3.7 nM).
3
Kalydeco16 IVACAFTOR Vertex Pharmaceuticals January of 2012
FDA Label: Kalydeco
Disease/s that Drug Treats:cystic fibrosis with the G551D mutation in the CFTR gene
Indications and Usage:16 KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R. KALYDECO is indicated for the treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. (1) Limitations of Use: * Not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene. (1, 14)
DrugBank Targets:14 Cystic fibrosis transmembrane conductance regulator
Mechanism of Action:16 
Target: cystic fibrosis transmembrane conductance regulator (CFTR)
Action: potentiator
FDA: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel-open probability (or gating) of the CFTR protein. In vitro, ivacaftor increased CFTR-mediated transepithelial current (IT) in rodent cells expressing the G551D-CFTR protein following addition of a cyclic adenosine monophosphate (cAMP) agonist with an EC50 of 100 ± 47 nM; however, ivacaftor did not increase IT in the absence of cAMP agonist. Ivacaftor also increased IT in human bronchial epithelial cells expressing G551D-CFTR protein following addition of a cAMP agonist by 10-fold with an EC50 of 236 ± 200 nM. Ivacaftor increased the open probability of G551D-CFTR protein in single channel patch clamp experiments using membrane patches from rodent cells expressing G551D-CFTR protein by 6-fold versus untreated cells after addition of PKA and ATP. In addition to G551D-CFTR, ivacaftor increased the channel-open probability of other mutant CFTR forms expressed in rodent cells, resulting in enhanced CFTR-mediated IT. These mutant CFTR forms included G178R-, S549N-, S549R-, G551S-, G970R-, G1244E-, S1251N-, S1255P-, and G1349D-CFTR. Ivacaftor also potentiated the channel-open probability of R117H-CFTR, which has low channel-open probability (gating) and reduced channel current amplitude (conductance) compared to normal CFTR. In vitro responses do not necessarily correspond to in vivo pharmacodynamic response or clinical benefit.

Drugs for Retinoblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 153)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
EtoposideapprovedPhase 4, Phase 3, Phase 2, Phase 1123233419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
 
Eposin, Vepesid, VP-16, Toposar, Etoposide
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
2
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 29042068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
3
CarboplatinapprovedPhase 4, Phase 3, Phase 2, Phase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
4
LenograstimapprovedPhase 4, Phase 3, Phase 2, Phase 11202135968-09-1
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
 
Granulocyte colony stimulating factor 3 (CHO cell derived)
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
5
Itraconazoleapproved, investigationalPhase 414784625-61-655283
Synonyms:
(+-)-1-sec-Butyl-4-(p-(4-(p-(((2R*,4S*)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-delta(sup 2)-1,2,4-triazolin-5-one
(+/-)-1-[( R *)- sec -butyl]-4-[ p -[4-[ p -[[(2 R *,4 S *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-(DELTA) 2 1,2,4-triazolin-5-one mixture with (+/-)-1-[( R *)- sec -butyl]-4-[ p -[4- [ p -[[(2 S *,4 R *)-2-(2,4-dichlorophenyl)-2-(1 H -1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl] phenyl]-(DELTA) 2 -1,2,4-triazolin-5-one
(1)-cis-4-(4-(4-(4-((2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2,4-dihydro-2-sec-butyl-3H-1,2,4-triazol-3-one
2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
2-butan-2-yl-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)
4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one
84604-65-9
84625-61-6
AC-542
AC1L1GQ5
AC1L1IRU
AC1OCEL7
AC1Q6EZ3
AKOS000280875
Ambap84625-61-6
BIDD:GT0796
BRN 6042047
C35H38Cl2N8O4
CHEBI:6076
CHEMBL22587
CHEMBL882
CID3793
CID55283
CID6917738
CID9961741
CPD000058959
Canadiol
D00350
DB01167
EINECS 283-347-2
FT-0082511
HMS2051K14
HMS2090M20
Hyphanox
I01-1043
I0732
ITC
ITCZ
ITZ
Intraconazole
 
Itraconazol
Itraconazol [Spanish]
Itraconazole
Itraconazole & Bovine Lactoferrin
Itraconazole & Nyotran
Itraconazole & Nyotran(Liposomal Nystatin)
Itraconazole (JAN/USAN)
Itraconazole [USAN:BAN:INN:JAN]
Itraconazole oral solution
Itraconazolum
Itraconazolum [Latin]
Itrizole
Itrizole (TN)
Itrizole (tn)
LS-1843
MLS000028582
MLS000759472
MLS000863291
MLS001148245
MolPort-000-883-864
MolPort-003-848-295
NCGC00089812-03
Oriconazole
Oriconazole, R51211, Sporanox
Orungal
Prokanazol
R 51211
R-51211
S2476_Selleck
SAM001246679
SMR000058959
Sempera
Spherazole
Sporal
Sporanos
Sporanox
Sporanox (TN)
Sporanox (tn)
Sporonox
TL8005525
Triasporn
UNII-304NUG5GF4
cis-Itraconazole
itraconazole
6
Miconazoleapproved, investigational, vet_approvedPhase 4, Phase 2, Phase 1362422916-47-84189
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
AKOS001574474
Aflorix(nitrate)
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
CPD-4501
Conofite(nitrate)
D00416
DB01110
Dactarin
Daktarin IV
Daktarin iv
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
LS-78378
Lotrimin AF(nitrate)
MCZ
MJR 1762
MLS002222203
Micantin (nitrate)
Miconasil Nitrate
 
Miconazol
Miconazol [INN-Spanish]
Miconazole
Miconazole (JP15/USP/INN)
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole [USAN:BAN:INN:JAN]
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (TN)
Monistat iv (tn)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
NSC 170986
NSC169434
NSC170986
Novo-Miconazole Vaginal Ovules
Oprea1_091955
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
Prestwick_335
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
STK834405
STOCK1S-93556
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
Spectrum_000965
UNII-7NNO0D7S5M
Vusion
Zimycan
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
miconazole
7
NicotineapprovedPhase 4105054-11-5942, 89594
Synonyms:
(−
(+)-Nicotine
(-)-3-(1-Methyl-2-pyrrolidyl)pyridine
(-)-3-(N-Methylpyrrolidino)pyridine
(-)-Nicotine
(-)-Nicotine solution
(2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine
(R)-3-(1-Methyl-2-pyrrolidinyl)pyridine
(R,S)-Nicotine
(S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE
(S)-(-)-Nicotine
(S)-(−)-nicotine
(S)-3-(1-methylpyrrolidin-2-yl)pyridine
(S)-3-(N-methylpyrrolidin-2-yl)pyridine
(S)-Nicotine
(−)-nicotine
)-1-Methyl-2-(3-pyridyl)pyrrolidine
)-Nicotine
)-Nicotine solution
1-Methyl-2-(3-pyridal)-Pyrrolidine
1-Methyl-2-(3-pyridal)-pyrrolidene
1-Methyl-2-(3-pyridiyl)pyrrolidine
1-Methyl-2-(3-pyridyl)pyrrolidine
1uw6
2'-beta-H-Nicotine
3-(1-Methyl-2-pyrollidinyl)pyridine
3-(1-Methyl-2-pyrrolidinyl)-Pyridine
3-(1-Methyl-2-pyrrolidinyl)pyridine
3-(1-Methylpyrrolidin-2-yl)pyridine
3-(2-(N-methylpyrrolidinyl))pyridine
3-(N-Methylpyrollidino)pyridine
3-(N-Methylpyrrolidino)pyridine
3-(N-methylpyrollidino)pyridine
3-N-Methylpyrrolidine
3-[(2S)-1-methylpyrrolidin-2-yl]pyridine
36733_FLUKA
36733_RIEDEL
434F7990-3240-4A43-ACEC-E6CC1E495FA0
46343_FLUKA
46343_RIEDEL
54-11-5
AC1L3I79
AC1Q3ZOC
AI3-03424
BB_NC-0777
BIDD:GT0599
BRD-K05395900-322-02-1
Black Leaf
Black Leaf 40
C00745
CCRIS 1637
CHEBI:17688
CHEMBL3
CID89594
CPD000059074
Campbell's Nico-Soap
Caswell No. 597
Commit
D-Nicotine
D03365
DL-tetrahydronicotyrine
Destruxol
Destruxol Orchid Spray
EINECS 200-193-3
ENT 3,424
EPA Pesticide Chemical Code 056702
Emo-Nik
Flux Maag
Fumeto bac
Fumetobac
HSDB 1107
Habitrol
Habitrol (TN)
L(-)-nicotine
L(−)-nicotine
L-3-(1-Methyl-2-pyrrolidyl)pyridine
 
L-Nicotine
LS-202
MLS001055457
MLS001335905
Mach-Nic
Methyl-2-pyrrolidinyl)pyridine
Micotine
MolPort-000-744-731
N3876_SIGMA
N5511_FLUKA
N5511_SIGMA
NCGC00090693-01
NCGC00090693-02
NCGC00090693-03
NCGC00090693-04
NCGC00090693-05
NCGC00090693-06
NCGC00090693-07
NCT
NICOTINE AND SALTS
NSC 5065
NSC97238
Niagara P.A. Dust
Nic-Sal
Nico-Dust
Nico-Fume
Nicocide
Nicoderm
Nicoderm Cq
Nicoderm Patch
Nicorette
Nicorette Plus
Nicotin
Nicotina
Nicotina [Italian]
Nicotine
Nicotine (USP)
Nicotine (compounds related to)
Nicotine Alkaloid
Nicotine Patch
Nicotine Polacrilex
Nicotine [BSI:ISO]
Nicotine [UN1654]
Nicotine [UN1654] [Poison]
Nicotine [USAN]
Nicotrol
Nicotrol Inhaler
Nicotrol Ns
Nictoine patch
Nikotin
Nikotin [German]
Nikotyna
Nikotyna [Polish]
Ortho N-4 Dust
Ortho N-5 Dust
PDSP1_000113
PDSP1_000465
PDSP2_000463
PDSP2_000555
Prostep
R)-(+)-Nicotine
RCRA waste no. P075
RCRA waste number P075
SAM002564224
SDCCGMLS-0066911.P001
SMR000059074
Tendust
Transdermal Nicotine
UN1654
a -N-Methylpyrrolidine
a-N-Methylpyrrolidine
alpha-N-Methylpyrrolidine
beta-Pyridyl-alpha-N-methyl pyrrolidine
beta-Pyridyl-alpha-N-methylpyrrolidine
bmse000105
delta-Nicotine
nicotine
nicotine replacement patch
8Ginsengapproved, nutraceuticalPhase 4, Phase 29250647-08-0
9Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 14945
10Antimitotic AgentsPhase 4, Phase 3, Phase 2, Phase 15498
11Antineoplastic Agents, PhytogenicPhase 4, Phase 3, Phase 2, Phase 15420
12Etoposide phosphatePhase 4, Phase 3, Phase 2, Phase 11232
13Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 121402
14Ibandronic acidPhase 480
15Adjuvants, ImmunologicPhase 4, Phase 3, Phase 2, Phase 12484
16Bone Density Conservation AgentsPhase 4, Phase 23266
17
CurcuminPhase 4137458-37-7969516
Synonyms:
1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione
1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione
C.I. Natural Yellow 3
CI Natural Yellow 3
Cucurmin
Curcuma
Curcumin
Curcumin I
Diferaloylmethane
Diferuloylmethane
Gelbwurz
Golden seal
Haidr
Halad
Haldar
Halud
Hydrastis
 
Indian saffron
Indian turmeric
Kacha haldi
Kurkumin [czech]
Merita earth
Natural yellow 3
Orange root
Safran D'inde
Souchet
Terra merita
Tumeric yellow
Turmeric
Turmeric (>98% curcurmin)
Turmeric oleoresin (79%-85% curcumin)
Turmeric yellow
Yellow ginger
Yellow puccoon
Yellow root
Yo-kin
Zlut prirodni 3 [Czech]
18Liver ExtractsPhase 4, Phase 2, Phase 13868
19DiphosphonatesPhase 4446
20Steroid Synthesis InhibitorsPhase 4, Phase 2, Phase 11718
21Cytochrome P-450 Enzyme InhibitorsPhase 43822
22Cytochrome P-450 CYP3A InhibitorsPhase 41666
23Antifungal AgentsPhase 4, Phase 2, Phase 13615
24HormonesPhase 4, Phase 2, Phase 113979
25Hormone AntagonistsPhase 4, Phase 2, Phase 112778
26Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 112767
27HydroxyitraconazolePhase 4147
28
AllantoinNutraceuticalPhase 4897-59-6204
Synonyms:
(S)-allantoin
2,5-Dioxo-4-imidazolidinyl-urea
4-Ureido-2,5-Imidazolidinedione
5-Ureido-Hydantoin
5-Ureidohydantoin
5-Ureidohydrantoin
AVC/Dienestrolcream
Alantan
Allantoin
Allantol
 
Alloxantin
Cordianine
D00121
Fancol TOIN
Glyoxyldiureid
Glyoxyldiureide
Glyoxylic diureide
N-(2,5-Dioxo-4-imidazolidinyl)urea
Psoralon
Sebical
Septalan
29
Topotecanapproved, investigationalPhase 3, Phase 2, Phase 1339119413-54-6, 123948-87-860700
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
123948-87-8
9-Dimethylaminomethyl-10-hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
LS-127395
 
MLS000759456
NCGC00178695-01
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
NChemBio.2007.10-comp24
NSC609699
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SMP2_000312
SMP2_000327
SMR000466344
TOPO
TOPOTECAN, HYCAMTIN
TPT
TTC
Topotecan (BAN)
Topotecan Hcl
Topotecan Hydrochloride
Topotecan Lactone
Topotecan Monohydrochloride, (S)-Isomer
Topotecan [INN:BAN]
Topotecan lactone
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
UNII-7M7YKX2N15
topotecan
30
ThiotepaapprovedPhase 3, Phase 2, Phase 121652-24-45453
Synonyms:
 
Thioplex
31
Doxorubicinapproved, investigationalPhase 3, Phase 2171423214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
32
CisplatinapprovedPhase 3, Phase 2269015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
33
MesnaapprovedPhase 3, Phase 2, Phase 125819767-45-4, 3375-50-6598
Synonyms:
2-Mercaptoethanesulfonate
2-Mercaptoethanesulfonic acid
 
2-mercaptoethane sulfonate Na
CoM
Coenzyme M
HS-CoM
34
Cyclophosphamideapproved, investigationalPhase 3, Phase 2, Phase 1, Early Phase 1282950-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
35
DoxilApproved June 1999Phase 3, Phase 2171431703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
36Immunosuppressive AgentsPhase 3, Phase 2, Phase 1, Early Phase 112770
37topoisomerase I inhibitorsPhase 3, Phase 2, Phase 11328
38Antineoplastic Agents, AlkylatingPhase 3, Phase 2, Phase 1, Early Phase 14474
39
IodinePhase 3, Phase 2, Phase 15467553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
40cadexomer iodinePhase 3, Phase 2, Phase 1514
41Anti-Bacterial AgentsPhase 3, Phase 2, Phase 1, Early Phase 110884
42Antibiotics, AntitubercularPhase 3, Phase 2, Phase 16972
43Antirheumatic AgentsPhase 3, Phase 2, Phase 1, Early Phase 110627
44AnestheticsPhase 3, Phase 29001
45Alkylating AgentsPhase 3, Phase 2, Phase 1, Early Phase 14694
46Anti-Infective Agents, LocalPhase 3, Phase 21785
47MicronutrientsPhase 3, Phase 25802
48Trace ElementsPhase 3, Phase 25802
49
RanibizumabapprovedPhase 2, Phase 1474347396-82-1459903
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
 
Ranibizumab
Ranibizumab (USAN/INN)
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
ranibizumab
rhuFab V2
50
Dexamethasoneapproved, investigational, vet_approvedPhase 2, Phase 1208450-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
 
Dexameth
Dexamethansone
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038

Interventional clinical trials:

(show top 50)    (show all 110)
idNameStatusNCT IDPhase
1CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular RetinoblastomaCompletedNCT02319486Phase 4
2Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell TransplantationCompletedNCT00336531Phase 4
3Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate SupplementationCompletedNCT02249741Phase 4
4The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile DysfunctionCompletedNCT02413099Phase 4
5Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical StudyCompletedNCT02204826Phase 4
6G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant TumorNot yet recruitingNCT02933333Phase 4
7Carboplatin Periocular Injection for RetinoblastomaUnknown statusNCT02137928Phase 3
8Does Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy?Unknown statusNCT01809522Phase 3
9Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular RetinoblastomaCompletedNCT00072384Phase 3
10Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed RetinoblastomaCompletedNCT00335738Phase 3
11Adjuvant Chemotherapy for High-risk Retinoblastoma After EnucleationRecruitingNCT01906814Phase 3
12Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular RetinoblastomaActive, not recruitingNCT00079417Phase 3
13Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular RetinoblastomaActive, not recruitingNCT00554788Phase 3
14Study of Treatment for Patients With Cancer of the Eye -RetinoblastomaActive, not recruitingNCT00186888Phase 3
15Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With CancerActive, not recruitingNCT01987596Phase 3
16Efficacy Study of Lucentis in the Treatment of RetinoblastomaUnknown statusNCT01899066Phase 2
17Chemotherapy Treatment for Children With Intraocular Germ-Line RetinoblastomaUnknown statusNCT00179920Phase 2
18Chemotherapy in Treating Patients With RetinoblastomaCompletedNCT00002675Phase 2
19Carboplatin Plus Vincristine in Treating Children With RetinoblastomaCompletedNCT00002794Phase 2
20Combination Chemotherapy, Radiation Therapy, and Bone Marrow Transplantation in Treating Patients With RetinoblastomaCompletedNCT00004006Phase 2
21Intra-arterial Chemotherapy(Chemosurgery) for RetinoblastomaCompletedNCT00901238Phase 1, Phase 2
22Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC.CompletedNCT01291017Phase 2
23Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00006102Phase 2
24High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid TumorsCompletedNCT00003173Phase 2
25Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid TumorsCompletedNCT00024258Phase 2
26Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2
27Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare CancerCompletedNCT00002515Phase 2
28An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.CompletedNCT00555906Phase 2
29Intra-arterial Chemotherapy for Children With RetinoblastomaRecruitingNCT00906113Phase 1, Phase 2
30Protocol for the Study and Treatment of Participants With Intraocular RetinoblastomaRecruitingNCT01783535Phase 2
31Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From GuatemalaRecruitingNCT01857752Phase 2
32Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)RecruitingNCT02870907Phase 2
33Conservative Treatments of RetinoblastomaRecruitingNCT02866136Phase 2
34Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line ChemotherapyRecruitingNCT02334527Phase 2
35A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate CancerRecruitingNCT02059213Phase 2
36Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB ExpressionRecruitingNCT02555189Phase 1, Phase 2
37A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation TherapyRecruitingNCT02607124Phase 1, Phase 2
38Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and SunitinibRecruitingNCT01907607Phase 2
39Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal CancerRecruitingNCT00445965Phase 2
40PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC TrialRecruitingNCT02624973Phase 2
41Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung CancerRecruitingNCT02487095Phase 1, Phase 2
42Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral RetinoblastomaActive, not recruitingNCT00110110Phase 2
43A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)Active, not recruitingNCT02806648Phase 2
44Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular DementiaActive, not recruitingNCT01761227Phase 2
45Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast CancerActive, not recruitingNCT00721409Phase 1, Phase 2
46Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell CarcinomaNot yet recruitingNCT03024489Phase 1, Phase 2
47Intra-arterial Chemotherapy for the Treatment of Intraocular RetinoblastomaTerminatedNCT01293539Phase 2
48Proton Beam Radiation Therapy for Intraocular and Periocular RetinoblastomaTerminatedNCT00432445Phase 2
49Intra-arterial Chemotherapy With Melphalan for the Treatment of Retinoblastoma (RTB) in Advanced Intraocular StageTerminatedNCT01393769Phase 2
50A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)TerminatedNCT01919229Phase 2

Search NIH Clinical Center for Retinoblastoma

Inferred drug relations via UMLS67/NDF-RT45:

Genetic Tests for Retinoblastoma

About this section

Genetic tests related to Retinoblastoma:

id Genetic test Affiliating Genes
1 Retinoblastoma, Trilateral26
2 Retinoblastoma26 24 RB1

Anatomical Context for Retinoblastoma

About this section

MalaCards organs/tissues related to Retinoblastoma:

35
Eye, Retina, Lung, Prostate, Bone, Pineal, Testes

FMA organs/tissues related to Retinoblastoma:

17
The pineal or suprasellar region

Animal Models for Retinoblastoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Retinoblastoma:

40 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000538110.2CDK4, E2F1, E2F3, E2F4, MDM2, RB1
2MP:000536910.2CDK4, E2F1, HDAC1, MDM2, RB1, RBL1
3MP:00053889.8ARID4A, E2F1, E2F3, E2F4, HDAC1, RB1
4MP:00053899.8ARID4A, CDK4, E2F1, E2F3, E2F4, MDM2
5MP:00053859.6ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
6MP:00107719.6ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
7MP:00053869.6ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
8MP:00028739.6CDK4, E2F1, E2F3, E2F4, HDAC1, KDM5A
9MP:00053799.4ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
10MP:00053879.4ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
11MP:00020069.2ARID4A, CDK4, E2F1, E2F4, HDAC1, KDM5A
12MP:00053809.1CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
13MP:00053849.1ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
14MP:00053909.0ARID4A, E2F1, E2F3, E2F4, MDM2, RB1
15MP:00053788.9ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1
16MP:00107688.7ARID4A, CDK4, E2F1, E2F3, E2F4, HDAC1

Publications for Retinoblastoma

About this section

Articles related to Retinoblastoma:

(show top 50)    (show all 2447)
idTitleAuthorsYear
1
Therapeutic Options for Retinoblastoma. (27218786)
2016
2
Genetic screening in Iranian patients with retinoblastoma. (27983729)
2016
3
Correlation of High Mobility Group Box-1 Protein (HMGB1) with Clinicopathological Parameters in Primary Retinoblastoma. (26118980)
2015
4
Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression. (25338120)
2014
5
Identification of a genetic interaction between the tumor suppressor EAF2 and the retinoblastoma protein (Rb) signaling pathway in C. elegans and prostate cancer cells. (24727455)
2014
6
Treatment outcome of osteosarcoma after bilateral retinoblastoma: a retrospective study of eight cases. (24795337)
2014
7
Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. (24577551)
2014
8
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. (23922798)
2013
9
Anti-apoptotic effect of clusterin on cisplatin-induced cell death of retinoblastoma cells. (24085287)
2013
10
Bilateral retinoblastoma in early infancy. (23584660)
2013
11
Clinical Pharmacokinetics of Intra-arterial Melphalan and Topotecan Combination in Patients with Retinoblastoma. (24359624)
2013
12
Correlation between clinical features, magnetic resonance imaging, and histopathologic findings in retinoblastoma: a prospective study. (22218144)
2012
13
IVF and retinoblastoma revisited. (22112645)
2012
14
The retinoblastoma protein is essential for survival of postmitotic neurons. (23077065)
2012
15
Retinoblastoma in the democratic republic of congo: 20-year review from a tertiary hospital in kinshasa. (22619679)
2012
16
Differential profiles of microRNAs in retinoblastoma cell lines of different proliferation and adherence patterns. (21941147)
2011
17
Bilateral retinoblastoma presenting at retinopathy of prematurity screening. (20576664)
2010
18
Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. (20461151)
2010
19
Effect of curcumin on lung resistance-related protein (LRP) in retinoblastoma cells. (19895312)
2009
20
Genomic differences between retinoma and retinoblastoma. (18785023)
2008
21
Retinoblastoma presenting as Coats' disease. (18049483)
2008
22
Spectrum of RB1 gene mutations and loss of heterozygosity in Mexican patients with retinoblastoma: identification of six novel mutations. (18503160)
2008
23
Ki-67 cell proliferation in familial and in esporadic unilateral retinoblastoma: case report. (17589712)
2007
24
Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression. (16908528)
2006
25
Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor-suppressive functions in highly metastatic melanoma cells. (16645588)
2006
26
Kinetic properties of nuclear transport conferred by the retinoblastoma (Rb) NLS. (15838894)
2005
27
Major histocompatibility antigens and antigen-processing molecules in retinoblastoma. (14983503)
2004
28
Retinoblastoma presenting as orbital cellulitis: report of four cases with a review of the literature. (15559956)
2004
29
The central acidic domain of MDM2 is critical in inhibition of retinoblastoma-mediated suppression of E2F and cell growth. (15485814)
2004
30
Docosahexaenoic acid membrane content and mRNA expression of acyl-CoA oxidase and of peroxisome proliferator-activated receptor-delta are modulated in Y79 retinoblastoma cells differently by low and high doses of alpha-linolenic acid. (13130515)
2003
31
Differentiation of human melanoma cells through p38 MAP kinase is associated with decreased retinoblastoma protein phosphorylation and cell cycle arrest. (12140374)
2002
32
Retinoblastoma family proteins induce differentiation and regulate B-myb expression in neuroblastoma cells. (11464857)
2001
33
Retinoblastoma protein complexes with C/EBP proteins and activates C/EBP-mediated transcription. (11596110)
2001
34
A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts. (10866689)
2000
35
Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. (10623718)
2000
36
Cytosine methylation transforms an E2F site in the retinoblastoma gene promoter into a binding site for the general repressor methylcytosine-binding protein 2 (MeCP2). (10390525)
1999
37
Genetics of retinoblastoma: a study. (9140452)
1997
38
Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. (8971152)
1996
39
Radiologic-pathologic correlation. Bilateral retinoblastoma with coexistent pinealoblastoma (trilateral retinoblastoma). (7900586)
1995
40
cDNA sequence and chromosomal localization of a novel human protein, RBQ-1 (RBBP6), that binds to the retinoblastoma gene product. (8595913)
1995
41
Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. (8521382)
1995
42
The retinoblastoma gene is involved in malignant progression of astrocytomas. (7979217)
1994
43
Trans-activation of the adenovirus E2 promoter by human papillomavirus type 16 E7 is mediated by retinoblastoma-dependent and -independent pathways. (8245866)
1993
44
Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. (1683797)
1991
45
Neuron-associated class III beta-tubulin isotype, microtubule-associated protein 2, and synaptophysin in human retinoblastomas in situ. Further immunohistochemical observations on the Flexner-Wintersteiner rosettes. (1703586)
1991
46
Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas. (1988704)
1991
47
Rapid inactivation and phosphorylation of pyroglutamyl peptidase II in Y-79 human retinoblastoma cells after exposure to phorbol ester. (1979029)
1990
48
The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. (3657987)
1987
49
Case of the month No. 69. Bilateral retinoblastoma. (6703911)
1984
50
Bilateral retinoblastoma: the prognosis for vision. (6882716)
1983

Variations for Retinoblastoma

About this section

UniProtKB/Swiss-Prot genetic disease variations for Retinoblastoma:

69 (show all 22)
id Symbol AA change Variation ID SNP ID
1RB1p.Glu72GlnVAR_005572
2RB1p.Glu137AspVAR_005573rs3092902
3RB1p.Ile185ThrVAR_005574
4RB1p.Arg358GlnVAR_005575rs767011440
5RB1p.Met457ArgVAR_005576
6RB1p.His549TyrVAR_005578
7RB1p.Ser567LeuVAR_005579rs137853292
8RB1p.Ala635ProVAR_005580
9RB1p.Val654GluVAR_005581
10RB1p.Arg661TrpVAR_005582rs137853294
11RB1p.Leu662ProVAR_005583
12RB1p.His673ProVAR_005584
13RB1p.Gln685ProVAR_005585
14RB1p.Cys706TyrVAR_005586
15RB1p.Cys712ArgVAR_005587rs137853296
16RB1p.Asn803LysVAR_005588
17RB1p.Arg358GlyVAR_010046
18RB1p.Lys447GlnVAR_010048
19RB1p.Lys530ArgVAR_010049
20RB1p.Leu657ProVAR_010050
21RB1p.Arg500GlyVAR_011580
22RB1p.Lys616GluVAR_011581

Clinvar genetic disease variations for Retinoblastoma:

5 (show all 103)
id Gene Variation Type Significance SNP ID Assembly Location
1RB1NM_000321.2(RB1): c.1723C> T (p.Gln575Ter)SNVPathogenicrs587778864GRCh37Chr 13, 49027156: 49027156
2RB1NM_000321.2(RB1): c.1735C> T (p.Arg579Ter)SNVPathogenicrs121913305GRCh37Chr 13, 49027168: 49027168
3RB1NM_000321.2(RB1): c.1738G> T (p.Glu580Ter)SNVPathogenicrs587778858GRCh37Chr 13, 49027171: 49027171
4RB1NG_009009.1: g.154289dupAduplicationPathogenicChr na, -1: -1
5RB1NM_000321.2(RB1): c.1909C> T (p.Gln637Ter)SNVPathogenicrs587778833GRCh37Chr 13, 49030434: 49030434
6RB1NM_000321.2(RB1): c.1925T> A (p.Leu642Ter)SNVPathogenicrs587778865GRCh37Chr 13, 49030450: 49030450
7RB1NM_000321.2(RB1): c.1927A> G (p.Lys643Glu)SNVPathogenicrs587778866GRCh37Chr 13, 49030452: 49030452
8RB1NM_000321.2(RB1): c.1960+5G> ASNVPathogenicrs587778871GRCh38Chr 13, 48456354: 48456354
9RB1NM_000321.2(RB1): c.1961-2A> TSNVPathogenicrs587778867GRCh37Chr 13, 49033822: 49033822
10RB1NM_000321.2(RB1): c.1973C> A (p.Ala658Asp)SNVPathogenicrs587778834GRCh37Chr 13, 49033836: 49033836
11RB1NM_000321.2(RB1): c.2101G> A (p.Asp701Asn)SNVPathogenicrs587778859GRCh37Chr 13, 49033964: 49033964
12RB1NM_000321.2(RB1): c.2107-1G> CSNVPathogenicrs587778860GRCh37Chr 13, 49037866: 49037866
13RB1NM_000321.2(RB1): c.2164A> T (p.Lys722Ter)SNVPathogenicrs587778849GRCh37Chr 13, 49037924: 49037924
14RB1NM_000321.2(RB1): c.2197C> T (p.His733Tyr)SNVPathogenicrs587778835GRCh37Chr 13, 49037957: 49037957
15RB1NM_000321.2(RB1): c.2209G> T (p.Glu737Ter)SNVPathogenicrs587778868GRCh37Chr 13, 49037969: 49037969
16RB1NG_009009.1: g.1662319T> ASNVPathogenicChr na, -1: -1
17RB1NM_000321.2(RB1): c.2227_2230dupTTGA (p.Lys745Aspfs)duplicationPathogenicrs587778836GRCh37Chr 13, 49039149: 49039152
18RB1NM_000321.2(RB1): c.2247T> A (p.Tyr749Ter)SNVPathogenicrs587778861GRCh37Chr 13, 49039169: 49039169
19RB1NG_009009.1: g.166501C> GSNVPathogenicChr na, -1: -1
20RB1NM_000321.2(RB1): c.2453delG (p.Gly818Valfs)deletionPathogenicrs587778837GRCh37Chr 13, 49039468: 49039468
21RB1NM_000321.2(RB1): c.2490-1G> ASNVPathogenicrs587778838GRCh37Chr 13, 49047495: 49047495
22RB1NM_000321.2(RB1): c.2520+1G> ASNVPathogenicrs587778850GRCh37Chr 13, 49047527: 49047527
23RB1NM_000321.2(RB1): c.2525dupC (p.Glu843Terfs)duplicationPathogenicrs587778851GRCh37Chr 13, 49050841: 49050841
24RB1NM_000321.2(RB1): c.2663+2T> CSNVPathogenicrs587778839GRCh37Chr 13, 49050981: 49050981
25RB1NM_000321.2(RB1): c.305_306delGT (p.Cys102Tyrfs)deletionPathogenicrs587778825GRCh37Chr 13, 48916775: 48916776
26RB1NM_000321.2(RB1): c.409G> T (p.Glu137Ter)SNVPathogenicrs121913296GRCh37Chr 13, 48919244: 48919244
27RB1NM_000321.2(RB1): c.438_441delTGCT (p.Asn146Lysfs)deletionPathogenicrs587778841GRCh37Chr 13, 48919273: 48919276
28RB1NM_000321.2(RB1): c.446C> G (p.Ser149Ter)SNVPathogenicrs587778870GRCh37Chr 13, 48919281: 48919281
29RB1NM_000321.2(RB1): c.463dupT (p.Tyr155Leufs)duplicationPathogenicrs587778854GRCh37Chr 13, 48919298: 48919298
30RB1NM_000321.2(RB1): c.508G> T (p.Glu170Ter)SNVPathogenicrs587778826GRCh37Chr 13, 48921968: 48921968
31RB1NG_009009.1: g.5168-?_5303+?(2)undetermined variantPathogenicChr na, -1: -1
32RB1NM_000321.2(RB1): c.72_74delGCC (p.Pro29del)deletionPathogenicrs587778823GRCh37Chr 13, 48878120: 48878122
33RB1NM_000321.2(RB1): c.103C> T (p.Gln35Ter)SNVPathogenicrs587778869GRCh37Chr 13, 48878151: 48878151
34NG_009009.1: g.5279_5281delGCCinsCTindelPathogenicChr na, -1: -1
35RB1NM_000321.2(RB1): c.763C> T (p.Arg255Ter)SNVPathogenicrs587778842GRCh37Chr 13, 48936995: 48936995
36RB1NM_000321.2(RB1): c.795delA (p.Lys265Asnfs)deletionPathogenicrs587778827GRCh37Chr 13, 48937027: 48937027
37RB1NM_000321.2(RB1): c.884dupA (p.Asn295Lysfs)duplicationPathogenicrs587778828GRCh37Chr 13, 48939052: 48939052
38RB1NM_000321.2(RB1): c.937G> T (p.Glu313Ter)SNVPathogenicrs587778843GRCh37Chr 13, 48939105: 48939105
39RB1NM_000321.2(RB1): c.958C> T (p.Arg320Ter)SNVPathogenicrs121913300GRCh37Chr 13, 48941648: 48941648
40RB1NM_000321.2(RB1): c.1021A> T (p.Lys341Ter)SNVPathogenicrs587778855GRCh37Chr 13, 48941711: 48941711
41RB1NM_000321.2(RB1): c.1024delA (p.Thr342Leufs)deletionPathogenicrs587778844GRCh37Chr 13, 48941714: 48941714
42RB1NM_000321.2(RB1): c.1049+1G> ASNVPathogenicrs587776782GRCh37Chr 13, 48941740: 48941740
43RB1NM_000321.2(RB1): c.1060_1061delCA (p.Gln354Glufs)deletionPathogenicrs587778829GRCh37Chr 13, 48942673: 48942674
44RB1NM_000321.2(RB1): c.1147dupC (p.Gln383Profs)duplicationPathogenicrs587778830GRCh37Chr 13, 48947560: 48947560
45RB1NM_000321.2(RB1): c.1166T> A (p.Leu389Ter)SNVPathogenicrs587778845GRCh37Chr 13, 48947579: 48947579
46RB1NM_000321.2(RB1): c.1215+1G> ASNVPathogenicrs587776783GRCh37Chr 13, 48947629: 48947629
47RB1NM_000321.2(RB1): c.1216-1G> ASNVPathogenicrs587778831GRCh37Chr 13, 48951053: 48951053
48RB1NM_000321.2(RB1): c.1332+1G> ASNVPathogenicrs587778846GRCh37Chr 13, 48951171: 48951171
49RB1NM_000321.2(RB1): c.1332+1G> TSNVPathogenicrs587778846GRCh37Chr 13, 48951171: 48951171
50RB1NM_000321.2(RB1): c.1346G> T (p.Gly449Val)SNVPathogenicrs587778847GRCh37Chr 13, 48953743: 48953743
51RB1NM_000321.2(RB1): c.1363C> T (p.Arg455Ter)SNVPathogenicrs121913302GRCh37Chr 13, 48953760: 48953760
52RB1NM_000321.2(RB1): c.1456_1457delTT (p.Leu486Ilefs)deletionPathogenicrs587778832GRCh37Chr 13, 48954335: 48954336
53RB1NM_000321.2(RB1): c.1472T> C (p.Leu491Pro)SNVPathogenicrs587778848GRCh37Chr 13, 48954351: 48954351
54RB1NM_000321.2(RB1): c.1654C> T (p.Arg552Ter)SNVPathogenicrs121913303GRCh37Chr 13, 48955538: 48955538
55RB1NM_000321.2(RB1): c.1688G> A (p.Trp563Ter)SNVPathogenicrs587778863GRCh37Chr 13, 48955572: 48955572
56RB1NM_000321.2(RB1): c.1695+1G> ASNVPathogenicrs587778857GRCh37Chr 13, 48955580: 48955580
57RB1NM_000321.2(RB1): c.217delA (p.Arg73Glufs)deletionPathogenicrs587778840GRCh37Chr 13, 48881495: 48881495
58RB1NM_000321.2(RB1): c.219_220delAG (p.Arg73Serfs)deletionPathogenicrs587778862GRCh37Chr 13, 48881497: 48881498
59RB1NM_000321.2(RB1): c.227_228dupTA (p.Thr77Terfs)duplicationPathogenicrs587778824GRCh37Chr 13, 48881505: 48881506
60RB1NM_000321.2(RB1): c.2520+1delGdeletionPathogenicrs587776779GRCh37Chr 13, 49047527: 49047527
61RB1NM_000321.2(RB1): c.1960+2T> CSNVPathogenicrs587776780GRCh37Chr 13, 49030487: 49030487
62RB1NM_000321.2(RB1): c.1333C> T (p.Arg445Ter)SNVPathogenicrs3092891GRCh37Chr 13, 48953730: 48953730
63RB1NM_000321.2(RB1): c.1700C> T (p.Ser567Leu)SNVPathogenicrs137853292GRCh37Chr 13, 49027133: 49027133
64RB1NM_000321.2(RB1): c.2359C> T (p.Arg787Ter)SNVPathogenicrs137853293GRCh37Chr 13, 49039374: 49039374
65RB1NM_000321.2(RB1): c.2244delG (p.Glu748Aspfs)deletionPathogenicrs587776781GRCh37Chr 13, 49039166: 49039166
66RB1NM_000321.2(RB1): c.1049+1G> TSNVPathogenicrs587776782GRCh37Chr 13, 48941740: 48941740
67RB1NM_000321.2(RB1): c.1072C> T (p.Arg358Ter)SNVPathogenicrs121913301GRCh37Chr 13, 48942685: 48942685
68RB1RB1, 5-BP DEL, EX8deletionPathogenicChr na, -1: -1
69RB1NM_000321.2(RB1): c.979_1033dup55 (p.Thr345Lysfs)duplicationPathogenicGRCh37Chr 13, 48941669: 48941723
70RB1NM_000321.2(RB1): c.1760_1769delAATCTGCTTG (p.Glu587Valfs)deletionPathogenicrs587776784GRCh37Chr 13, 49027193: 49027202
71RB1NM_000321.2(RB1): c.1949_1957delTTTATAAAA (p.Phe650_Lys928del)deletionPathogenicrs587776785GRCh37Chr 13, 49030474: 49030482
72RB1NM_000321.2(RB1): c.2212-1G> ASNVPathogenicrs587776786GRCh37Chr 13, 49039133: 49039133
73RB1NM_000321.2(RB1): c.-189G> TSNVPathogenicrs387906520GRCh37Chr 13, 48877860: 48877860
74RB1NM_000321.2(RB1): c.-198G> ASNVPathogenicrs387906521GRCh37Chr 13, 48877851: 48877851
75RB1NM_000321.2(RB1): c.1981C> T (p.Arg661Trp)SNVPathogenicrs137853294GRCh37Chr 13, 49033844: 49033844
76RB1RB1, GLN675TERSNVPathogenicChr na, -1: -1
77RB1NM_000321.2(RB1): c.2211G> A (p.Glu737=)SNVPathogenicrs587776787GRCh37Chr 13, 49037971: 49037971
78RB1NM_000321.2(RB1): c.1666C> T (p.Arg556Ter)SNVPathogenicrs121913304GRCh37Chr 13, 48955550: 48955550
79RB1NM_000321.2(RB1): c.1439_1441delACA (p.Asn480del)deletionPathogenicrs587776788GRCh37Chr 13, 48954318: 48954320
80RB1NM_000321.2(RB1): c.2134T> C (p.Cys712Arg)SNVPathogenicrs137853296GRCh37Chr 13, 49037894: 49037894
81RB1NM_000321.2(RB1): c.607+1G> TSNVPathogenicrs587776789GRCh37Chr 13, 48923160: 48923160
82RB1NM_000321.2(RB1): c.1818T> A (p.Tyr606Ter)SNVPathogenicrs137853297GRCh37Chr 13, 49030343: 49030343
83RB1NM_000321.2(RB1): c.43_65dup23 (p.Pro23Leufs)duplicationPathogenicrs587776790GRCh37Chr 13, 48878091: 48878113
84RB1NM_000321.2(RB1): c.2490-1398A> GSNVPathogenicrs587776791GRCh37Chr 13, 49046098: 49046098
85RB1NM_000321.2(RB1): c.1421+12_1421+32deldeletionPathogenicrs587781256GRCh37Chr 13, 48954232: 48954252
86RB1NM_000321.2(RB1): c.1907delT (p.Phe636Serfs)deletionPathogenicrs587781257GRCh37Chr 13, 49030432: 49030432
87RB1NM_000321.2(RB1): c.54_79del26 (p.Glu19Profs)deletionPathogenicrs727504120GRCh37Chr 13, 48878102: 48878127
88RB1NM_000321.2(RB1): c.1191delA (p.Glu398Lysfs)deletionPathogenicrs727504121GRCh37Chr 13, 48947604: 48947604
89RB1NM_000321.2(RB1): c.1401_1411dupATTATCCATTC (p.Gln471Hisfs)duplicationPathogenicrs797044649GRCh37Chr 13, 48954200: 48954210
90RB1NM_000321.2(RB1): c.1696-1G> ASNVPathogenicrs794727199GRCh37Chr 13, 49027128: 49027128
91RB1NM_000321.2(RB1): c.2370C> A (p.Tyr790Ter)SNVPathogenicrs794727372GRCh37Chr 13, 49039385: 49039385
92RB1NM_000321.2(RB1): c.297G> A (p.Trp99Ter)SNVPathogenicrs794727481GRCh37Chr 13, 48916767: 48916767
93RB1NM_000321.2(RB1): c.1154T> G (p.Leu385Ter)SNVPathogenicrs878853947GRCh37Chr 13, 48947567: 48947567
94RB1NM_000321.2(RB1): c.1814+3A> CSNVLikely pathogenicrs376886420GRCh38Chr 13, 48453114: 48453114
95RB1NM_000321.2(RB1): c.2053C> T (p.Gln685Ter)SNVPathogenicrs878853949GRCh37Chr 13, 49033916: 49033916
96RB1NM_000321.2(RB1): c.376delA (p.Ile126Serfs)deletionPathogenicrs886042357GRCh37Chr 13, 48916846: 48916846
97RB1NM_000321.2(RB1): c.2548C> T (p.Gln850Ter)SNVPathogenicrs886042935GRCh37Chr 13, 49050864: 49050864
98RB1NM_000321.2(RB1): c.1510C> T (p.Gln504Ter)SNVPathogenicrs886043247GRCh37Chr 13, 48955394: 48955394
99RB1NM_000321.2(RB1): c.396delT (p.Phe132Leufs)deletionPathogenicrs886043313GRCh37Chr 13, 48919231: 48919231
100RB1NM_000321.2(RB1): c.2489+1G> CSNVPathogenicrs764754259GRCh37Chr 13, 49039505: 49039505
101RB1NM_000321.2(RB1): c.1399C> T (p.Arg467Ter)SNVPathogenicrs398123331GRCh37Chr 13, 48954198: 48954198
102RB1NM_000321.2(RB1): c.1585dupT (p.Tyr529Leufs)duplicationPathogenicrs398123332GRCh37Chr 13, 48955469: 48955469
103RB1NM_000321.2(RB1): c.2067_2079delGAATGAGTATGAAinsCAC (p.Gln689Hisfs)indelPathogenicrs398123333GRCh37Chr 13, 49033930: 49033942

Cosmic variations for Retinoblastoma:

8 (show all 38)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1COSM889RB1eye,retina,retinoblastoma,NSc.2158A>Tp.K720*29
2COSM890RB1eye,retina,retinoblastoma,NSc.409G>Tp.E137*29
3COSM3724517RB1eye,retina,retinoblastoma,NSc.862-5T>Gp.?29
4COSM895RB1eye,retina,retinoblastoma,NSc.1363C>Tp.R455*29
5COSM1030RB1eye,retina,retinoblastoma,NSc.1961-1G>Ap.?29
6COSM521KRASeye,retina,retinoblastoma,NSc.35G>Ap.G12D29
7COSM878RB1eye,retina,retinoblastoma,NSc.751C>Tp.R251*29
8COSM891RB1eye,retina,retinoblastoma,NSc.958C>Tp.R320*29
9COSM1636648RB1eye,retina,retinoblastoma,NSc.2106+2T>Gp.?29
10COSM936RB1eye,retina,retinoblastoma,NSc.1183C>Tp.Q395*29
11COSM888RB1eye,retina,retinoblastoma,NSc.1666C>Tp.R556*29
12COSM882RB1eye,retina,retinoblastoma,NSc.2152G>Ap.D718N29
13COSM876RB1eye,retina,retinoblastoma,NSc.160G>Tp.E54*29
14COSM887RB1eye,retina,retinoblastoma,NSc.1654C>Tp.R552*29
15COSM764PIK3CAeye,retina,retinoblastoma,NSc.1634A>Gp.E545G29
16COSM13117RB1eye,retina,retinoblastoma,NSc.2053C>Tp.Q685*29
17COSM877RB1eye,retina,retinoblastoma,NSc.341C>Ap.S114*29
18COSM1041RB1eye,retina,retinoblastoma,NSc.1049+1G>Tp.?29
19COSM943RB1eye,retina,retinoblastoma,NSc.763C>Tp.R255*29
20COSM1050RB1eye,retina,retinoblastoma,NSc.1421G>Ap.S474N29
21COSM880RB1eye,retina,retinoblastoma,NSc.1333C>Tp.R445*29
22COSM910RB1eye,retina,retinoblastoma,NSc.1467C>Ap.C489*29
23COSM144722RB1eye,retina,retinoblastoma,NSc.265-2A>Cp.?29
24COSM1026RB1eye,retina,retinoblastoma,NSc.2326-2A>Cp.?29
25COSM1016RB1eye,retina,retinoblastoma,NSc.1960+1G>Ap.?29
26COSM3724518RB1eye,retina,retinoblastoma,NSc.2520+4A>Gp.?29
27COSM1015RB1eye,retina,retinoblastoma,NSc.1215+1G>Ap.?29
28COSM1014RB1eye,retina,retinoblastoma,NSc.1216-2A>Gp.?29
29COSM1040RB1eye,retina,retinoblastoma,NSc.1960+2T>Cp.?29
30COSM938RB1eye,retina,retinoblastoma,NSc.967G>Tp.E323*29
31COSM3724510RB1eye,retina,retinoblastoma,NSc.2527G>Tp.E843*29
32COSM942RB1eye,retina,retinoblastoma,NSc.2063T>Cp.L688P29
33COSM1013RB1eye,retina,retinoblastoma,NSc.1389+1G>Cp.?29
34COSM903RB1eye,retina,retinoblastoma,NSc.1494T>Ap.Y498*29
35COSM911RB1eye,retina,retinoblastoma,NSc.1166T>Ap.L389*29
36COSM1047RB1eye,retina,retinoblastoma,NSc.982A>Cp.N328H29
37COSM520KRASeye,retina,retinoblastoma,NSc.35G>Tp.G12V29
38COSM1017RB1eye,retina,retinoblastoma,NSc.380+1G>Tp.?29

Copy number variations for Retinoblastoma from CNVD:

6 (show top 50)    (show all 60)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1137531127800000LossTP73Retinoblastoma
2171871141465960179620513GainMCL1Retinoblastoma
3171881141465960179620513GainMUC1Retinoblastoma
4171891141465960179620513GainSHC1Retinoblastoma
53590316870000069500000Copy numberRetinoblastoma
63976110119100000135374737Copy numberMGMTRetinoblastoma
74968611110000000120700000LossIGSF4Retinoblastoma
85153411127676090128202918LosseETS1Retinoblastoma
953561113100000036400000Copy numberCD44Retinoblastoma
1053578113100000036400000GainPAX6Retinoblastoma
1153580113100000036400000GainWT1Retinoblastoma
1257117116310000076700000Copy numberGSTP1Retinoblastoma
136448212128700000132349534LossCHFRRetinoblastoma
1475253131840000022200000Copy numberRetinoblastoma
1576125132780000031100000LossBRCA2Retinoblastoma
1676619133362325978516556LosseARLTS1Retinoblastoma
1776620133362325978516556LosseRB1Retinoblastoma
1877033133950000052200000Copy numberRetinoblastoma
1977039133950000052200000DeletionHTR2ARetinoblastoma
2077041133950000052200000DeletionNUFIP1Retinoblastoma
2177043133950000052200000DeletionPCDH17Retinoblastoma
2277045133950000052200000DeletionPCDH8Retinoblastoma
2377635134620000048900000Copy numberRetinoblastoma
2477647134620000048900000LossRB1Retinoblastoma
2577992134887788349056026MutationRB1Retinoblastoma
2680983141106368585Copy numberRetinoblastoma
2787295147290000078400000GainMLH3Retinoblastoma
2889229151410000018400000Copy numberRetinoblastoma
2994758157040000073100000Copy numberRetinoblastoma
3098276161670000027600000GainPYCARDRetinoblastoma
31102221165067462557636204LosseCYLDRetinoblastoma
32102222165067462557636204LosseRBL2Retinoblastoma
33106052168560000087200000LossCDH13Retinoblastoma
3411654517680000011200000LossTP53Retinoblastoma
35119289181090000015400000Copy numberRetinoblastoma
361206301829000007200000Copy numberRetinoblastoma
3712414819163811651Copy numberRetinoblastoma
3813775321512036017242742GainDDX1Retinoblastoma
3913775421512036017242742GainMYCNRetinoblastoma
4014628124760000061100000Copy numberMSH6Retinoblastoma
41155742205790000062435964LossGATA5Retinoblastoma
4216607131199501827Copy numberRetinoblastoma
431791783870000011500000GainVHLRetinoblastoma
44200479555800000115200000GainAPCRetinoblastoma
45204222610808358827841GainCCND3Retinoblastoma
46204223610808358827841GainDEKRetinoblastoma
47204224610808358827841GainE2F3Retinoblastoma
48204225610808358827841GainIRF4Retinoblastoma
49204226610808358827841GainPIM1Retinoblastoma
502068736149100000152600000GainESRRetinoblastoma

Expression for genes affiliated with Retinoblastoma

About this section
Search GEO for disease gene expression data for Retinoblastoma.

Pathways for genes affiliated with Retinoblastoma

About this section

Pathways related to Retinoblastoma according to GeneCards Suite gene sharing:

(show all 47)
idSuper pathwaysScoreTop Affiliating Genes
110.1RB1, RBL1, RBL2
210.1HDAC1, MDM2
310.0E2F1, MDM2, RB1
410.0HDAC1, RBBP4, RBBP7
510.0HDAC1, RBBP4, RBBP7
69.9CDK4, E2F1, RB1, RBL2
79.8E2F1, HDAC1, RB1, RBBP8
89.8E2F1, HDAC1, RBBP4, RBBP7
99.8CDK4, E2F1, E2F3, RB1
109.8E2F1, E2F4, RB1, RBL1, RBL2
11
Show member pathways
9.8E2F4, HDAC1, RBL1, TFDP1
12
Show member pathways
9.7ARID4A, HDAC1, RBBP4, RBBP7
13
Show member pathways
9.7E2F1, E2F4, RBL1, RBL2, TFDP1
14
Show member pathways
9.7CDK4, E2F1, E2F4, MDM2, RB1
159.7CDK4, E2F1, E2F4, MDM2, RBL1
169.6CDK4, E2F1, HDAC1, MDM2, RB1
179.6CDK4, E2F1, E2F3, MDM2, RB1
18
Show member pathways
9.6CDK4, E2F1, E2F3, MDM2, RB1
199.6E2F1, E2F3, E2F4, RB1, TFDP1
209.6HDAC1, KDM5A, RBBP4, RBBP5, RBBP7
219.6CDK4, E2F1, MDM2, RB1, RBBP8, RBL2
229.6CDK4, E2F1, E2F3, MDM2, TFDP1
23
Show member pathways
9.6CDK4, E2F1, E2F4, RB1, RBL2, TFDP1
249.5CDK4, HDAC1, MDM2, RB1, RBL1, RBL2
259.5E2F1, HDAC1, MDM2, RB1, RBBP4, RBBP7
269.5CDK4, HDAC1, RBBP4, RBBP7, RBL1, TFDP1
279.5CDK4, E2F1, E2F3, E2F4, MDM2, RB1
289.4E2F4, HDAC1, MDM2, RB1, RBBP4, TFDP1
299.4CDK4, E2F1, E2F4, RB1, RBL1, RBL2
30
Show member pathways
9.4E2F1, E2F3, E2F4, HDAC1, RB1, RBBP8
31
Show member pathways
9.4E2F4, HDAC1, RB1, RBBP4, RBBP7, RBL1
329.4CDK4, E2F1, E2F3, HDAC1, MDM2, RB1
33
Show member pathways
9.4CDK4, E2F1, E2F3, HDAC1, MDM2, RB1
349.3CDK4, E2F4, HDAC1, RB1, RBL1, RBL2
35
Show member pathways
9.2ARID4A, CDK4, HDAC1, KDM5A, RBBP4, RBBP5
36
Show member pathways
9.2CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
37
Show member pathways
9.2CDK4, E2F1, E2F3, MDM2, RB1, RBBP4
38
Show member pathways
9.1CDK4, E2F1, E2F3, E2F4, MDM2, RB1
39
Show member pathways
9.0CDK4, E2F1, E2F3, E2F4, HDAC1, RB1
408.9CDK4, E2F1, E2F3, HDAC1, MDM2, RB1
41
Show member pathways
8.9E2F1, E2F4, HDAC1, MDM2, RBBP4, RBBP7
428.8E2F1, E2F3, E2F4, HDAC1, RB1, RBBP4
43
Show member pathways
8.8CDK4, E2F1, E2F3, E2F4, HDAC1, RB1
44
Show member pathways
8.8CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
45
Show member pathways
8.7DDX1, E2F1, E2F4, HDAC1, MDM2, RBBP4
46
Show member pathways
8.6CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2
47
Show member pathways
8.3CDK4, E2F1, E2F3, E2F4, HDAC1, MDM2

GO Terms for genes affiliated with Retinoblastoma

About this section

Cellular components related to Retinoblastoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1Rb-E2F complexGO:003518911.0E2F1, RB1
2ESC/E(Z) complexGO:003509811.0RBBP4, RBBP7
3Sin3 complexGO:001658010.8HDAC1, RBBP4
4chromatinGO:000078510.6CDK4, HDAC1, RB1
5NuRD complexGO:001658110.6HDAC1, RBBP4, RBBP7
6transcription factor complexGO:00056679.7CDK4, E2F1, E2F3, E2F4, RB1, RBL1
7nuclear chromatinGO:00007909.5E2F1, E2F4, HDAC1, RBBP4
8nucleolusGO:00057309.3CDK4, KDM5A, MDM2, RBBP5, RBBP6, RBBP8
9nucleusGO:00056347.5ARID4A, CDK4, DDX1, E2F1, E2F4, HDAC1
10nucleoplasmGO:00056547.3ARID4A, CDK4, DDX1, E2F1, E2F3, E2F4

Biological processes related to Retinoblastoma according to GeneCards Suite gene sharing:

(show all 19)
idNameGO IDScoreTop Affiliating Genes
1negative regulation of transcription involved in G1/S transition of mitotic cell cycleGO:007193011.0E2F1, RB1
2cellular response to xenobiotic stimulusGO:007146611.0E2F1, RB1
3regulation of lipid kinase activityGO:004355010.8RB1, RBL1, RBL2
4cell cycle checkpointGO:000007510.8RB1, RBBP8
5negative regulation of fat cell proliferationGO:007034510.6E2F1, E2F3, TFDP1
6G1/S transition of mitotic cell cycleGO:000008210.5CDK4, RB1, RBBP8
7chromatin remodelingGO:000633810.5HDAC1, RB1, RBBP4
8histone deacetylationGO:001657510.4ARID4A, HDAC1, RBBP4, RBBP7
9DNA replicationGO:000626010.3RBBP4, RBBP6, RBBP7, RBBP8
10covalent chromatin modificationGO:001656910.3RB1, RBL1, RBL2
11DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.3E2F1, E2F4, MDM2, RBL2, TFDP1
12regulation of cell cycleGO:005172610.2CDK4, E2F1, RB1, RBBP4, RBL1
13regulation of signal transduction by p53 class mediatorGO:190179610.1HDAC1, MDM2, RBBP4, RBBP7, RBBP8
14negative regulation of gene expressionGO:001062910.1HDAC1, MDM2, RB1, RBL1, RBL2
15positive regulation of transcription, DNA-templatedGO:004589310.0E2F1, E2F3, HDAC1, KDM5A, RB1
16negative regulation of transcription, DNA-templatedGO:00458929.4ARID4A, E2F1, HDAC1, MDM2, RB1, RBBP7
17positive regulation of transcription from RNA polymerase II promoterGO:00459449.3ARID4A, E2F1, E2F4, HDAC1, RB1, RBL1
18transcription, DNA-templatedGO:00063518.9DDX1, E2F1, HDAC1, PRDM2, RB1, RBBP4
19negative regulation of transcription from RNA polymerase II promoterGO:00001228.9E2F1, HDAC1, KDM5A, MDM2, RB1, RBBP7

Molecular functions related to Retinoblastoma according to GeneCards Suite gene sharing:

(show all 8)
idNameGO IDScoreTop Affiliating Genes
1promoter-specific chromatin bindingGO:199084110.5E2F4, RBL1, RBL2
2histone deacetylase activityGO:000440710.4ARID4A, HDAC1, RBBP4, RBBP7
3core promoter bindingGO:000104710.3E2F1, E2F3, HDAC1, RB1
4transcription regulatory region DNA bindingGO:004421210.3ARID4A, E2F1, HDAC1, RBBP5
5transcription factor bindingGO:00081349.9E2F1, E2F4, HDAC1, RB1, RBL1, TFDP1
6transcription factor activity, sequence-specific DNA bindingGO:00037009.3ARID4A, E2F1, E2F3, E2F4, HDAC1, KDM5A
7DNA bindingGO:00036778.8ARID4A, DDX1, E2F1, E2F3, E2F4, KDM5A
8protein bindingGO:00055157.4CDK4, DDX1, E2F1, E2F3, E2F4, HDAC1

Sources for Retinoblastoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
26GTR
27HGMD
28HMDB
29ICD10
30ICD10 via Orphanet
31ICD9CM
32IUPHAR
33KEGG
36MedGen
38MeSH
39MESH via Orphanet
40MGI
43NCI
44NCIt
45NDF-RT
48NINDS
49Novoseek
51OMIM
52OMIM via Orphanet
56PubMed
57QIAGEN
62SNOMED-CT via Orphanet
66Tumor Gene Family of Databases
67UMLS
68UMLS via Orphanet